Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases

Phase 2 Completed 198 enrolled University of Karachi Center for Bioequivalence Studies and Clinical Research · collab Zhuzhou Qianjin Pharmaceutical Co., Ltd., 801, Zhuzhou, China · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized, double blind and positive-controlled clinical trial to assess the efficacy and safety of Fuke Qianjin Capsule compared to Doxycycline Hyclate Tablet in patients with mild to medium PID and its sequalae.

Timeline

Start: 2021-09-21
Primary completion: 2022-03-11
Completion: 2022-03-11

Publications

Shah MR, Khan SN, Fatima S, Yao L, Yuan H, Ullah S, Ainuddin J, Zeng C, Zheng Y, Sahar N, Anwar S, Zhu M, Ma C, Kumari K, Wang W, Liu R. A randomized, double-blind, positive-controlled, Phase-II clinical trial to evaluate efficacy and safety of Fuke Qianjin capsule in Pakistani patients with pelvic inflammatory disease. Front Pharmacol. 2024 Mar 22;15:1287321. doi: 10.3389/fphar.2024.1287321. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxycycline hyclate	Small molecule	0.1 g	Oral
Subject	Fuke Qianjin capsule	Unknown	—	Oral
Subject	Metronidazole	Small molecule	0.4 g	Oral

Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases

Summary

Timeline

Publications

Drugs

Indications